The GLP-1 market created one of the fastest growth periods in the history of direct-to-consumer healthcare. In the span of a few years, telehealth brands built entire businesses around prescribing semaglutide and tirzepatide, and demand showed no signs of slowing. Then the regulatory environment shifted, and the brands that had built compliant infrastructure kept scaling while the ones that hadn't found themselves scrambling.
That shift is the context every operator building a GLP-1 telehealth platform in 2026 needs to understand before they evaluate technology, hire providers, or take on their first patient. The opportunity is still real: GLP-1 prescribing through telehealth remains legal, growing, and in high demand. The infrastructure required to do it compliantly has just become more specific.
At Bask Health, we work with healthcare brands building exactly this kind of program. This guide draws on current Telehealth.HHS.gov guidance and HRSA's telehealth framework to lay out what the GLP-1 telehealth landscape looks like right now and what a platform needs to handle to operate well in it.
Key Takeaways
- GLP-1 telehealth prescribing is legal and active across all 50 states; the regulatory shift affected compounded versions, not branded prescribing.
- The FDA resolved the semaglutide shortage in February 2025, and the tirzepatide shortage in late 2024, ending the window during which mass compounding of essentially identical copies was broadly permissible.
- As of 2026, compliant GLP-1 telehealth businesses operate primarily through branded prescriptions (Wegovy, Zepbound, Ozempic, Mounjaro) or narrowly compliant 503A patient-specific compounding with documented clinical necessity.
- The infrastructure required for compliant GLP-1 prescribing is more rigorous than a generic telehealth platform: intake must screen for eligibility, e-prescribing must connect to licensed pharmacies, and patient follow-up must be built into the clinical model.
- Brands that built robust clinical infrastructure before the regulatory shift kept growing through it; brands that relied on loose intake and mass compounding did not.
- Bask Health provides the infrastructure layer that GLP-1 telehealth brands need, from intake to e-prescribing to order management, in a single connected platform.
What Changed, and What Didn't
It's worth being direct about this because the misinformation circulating in the GLP-1 operator space poses real compliance risks for new entrants.
What changed: the FDA officially resolved the semaglutide injection shortage on February 21, 2025, and the tirzepatide injection shortage in late 2024. Under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are restricted from producing essentially identical copies of commercially available FDA-approved drugs once those drugs are no longer in shortage. The FDA has been clear that tirzepatide and semaglutide no longer appear on the drug shortage list or the 503B bulks list, and grace periods for enforcement discretion have ended.
What didn't change: prescribing branded GLP-1 medications via telehealth remains entirely legal and continues to operate normally. A licensed telehealth provider can prescribe Wegovy, Zepbound, Ozempic, or Mounjaro to a qualifying patient via a virtual visit, and the prescription is processed through a licensed pharmacy just as it would be for an in-person appointment. Narrow 503A patient-specific compounding also remains available where a prescriber documents a clinically significant difference from commercially available products for an identified individual patient.
The GLP-1 opportunity in telehealth hasn't closed. The companies operating in it have had to run a tighter clinical model than in 2022.
Direct Answer: Is GLP-1 Telehealth Still a Viable Business in 2026?
Yes, with the right infrastructure and clinical model. Branded GLP-1 prescribing through telehealth is legal, and patient demand remains strong. The brands succeeding in this space in 2026 are the ones that built their programs around rigorous intake screening, connected e-prescribing, genuine clinical follow-up, and reliable pharmacy coordination, not the ones that relied on loose intake and mass-compounded supply. The regulatory environment has made clinical infrastructure a competitive advantage, not just a compliance requirement.
What a GLP-1 Telehealth Platform Needs
The infrastructure requirements for a compliant, scalable GLP-1 telehealth program are more specific than for a general-purpose virtual care platform. Here is what actually matters.
Rigorous, Condition-Specific Intake
GLP-1 prescribing has specific eligibility criteria, BMI thresholds, comorbidity documentation, and contraindication screening that need to be built into the intake flow, not left to providers to catch during a brief asynchronous review. An intake form that doesn't screen for eligibility at the point of submission creates clinical risk, documentation gaps, and a pattern that draws regulatory scrutiny.
A well-designed GLP-1 intake flow collects BMI, weight history, relevant comorbidities, current medications (particularly anything that interacts with GLP-1 agonists), and contraindication flags before a provider ever reviews the case. It should also be configurable because the clinical questions for a semaglutide program differ from those for a tirzepatide program, and a platform that requires engineering work every time intake needs to change creates operational drag.
Bask Health's drag-and-drop questionnaire builder lets clinical teams design and iterate on condition-specific intake flows without writing code. For GLP-1 programs specifically, this means the eligibility screening, medical history collection, and contraindication logic can be built and updated by clinical staff as protocols evolve, which they have, regularly, over the past two years.
Connected E-Prescribing
A provider who completes a GLP-1 intake review and then has to log into a separate e-prescribing system to send the prescription introduces a workflow gap that slows throughput and creates documentation errors. For a high-volume GLP-1 program, that friction compounds quickly.
The right model keeps clinical documentation and prescribing in the same workflow. When a provider approves a GLP-1 consultation, the prescription should route directly from the platform to the patient's pharmacy of choice, whether that's a national retail chain processing a branded prescription through insurance, or a licensed pharmacy coordinating a patient-specific compounded formulation under documented 503A criteria. Bask Health's EMR and e-prescribing tools keep both connected, so the clinical encounter and the prescription are part of the same record rather than two separate systems that need to be manually reconciled.
Patient Follow-Up Built Into the Platform
This is the piece that most generic telehealth platforms handle worst, and it's the piece that the 2026 GLP-1 landscape makes most important. Regulators and state medical boards are paying attention to platforms that prescribe GLP-1 medications with minimal clinical follow-up. Genuine ongoing care dosage adjustment check-ins, side effect monitoring, and weight progress review isn't just good clinical practice. It's what separates a compliant telehealth program from one that reads like a prescription vending machine.
That follow-up needs to be embedded in the platform, not an afterthought. Providers need visibility into which patients are due for a check-in, which patients have outstanding follow-up messages, and which patients are approaching a refill that requires clinical review before it goes out. Bask Health's patient management tools give clinical teams visibility across their entire patient population, so follow-up happens systematically, not only when a patient proactively reaches out.
Pharmacy Coordination and Order Management
For DTC GLP-1 brands that coordinate pharmacy fulfillment, directly routing prescriptions to network pharmacies and managing the delivery side of the patient journey, order management infrastructure matters as much as the clinical platform. A patient who gets a prescription approved but receives no communication about their order, shipping status, or refill timeline has a broken experience, regardless of how good the clinical visit was.
Bask Health's pharmacy fulfillment and order management tools handle this side of the patient journey, connecting the clinical prescription to the fulfillment and delivery workflow so the patient experience remains coherent from intake through to medication delivery.
Security and HIPAA Compliance at the Infrastructure Level
GLP-1 programs collect sensitive health information weight, BMI, metabolic history, comorbidities and process it through clinical and pharmacy workflows that all touch protected health information. The compliance architecture needs to hold up across every touchpoint, not just the video call. Bask Health's security infrastructure covers data handling, access controls, and HIPAA compliance at the platform level, including business associate agreement coverage across the system rather than just the patient-facing layer.
What the Regulatory Shift Means for New Entrants
For operators building a GLP-1 telehealth program today, the post-shortage regulatory environment is actually clarifying rather than restricting. The rules are clearer than they were in 2022, when the shortage created a window that many operators treated as permanent. Branded prescribing is straightforward. Patient-specific compounding under 503A is available for documented cases. The programs that get into trouble are the ones that try to replicate the 2022–2024 model in a 2026 regulatory environment.
The practical implication for platform selection is that the intake, documentation, and follow-up infrastructure that once felt like a nice-to-have is now a baseline requirement. A platform that doesn't support rigorous clinical intake, connected prescribing, and systematic follow-up isn't just a suboptimal choice for a GLP-1 program; it's an operational liability.
Direct Answer: What Does a GLP-1 Telehealth Platform Need That Generic Platforms Don't?
Condition-specific intake screening that covers eligibility criteria and contraindications before provider review; e-prescribing integrated directly into the clinical workflow; systematic patient follow-up tools that provide providers with visibility across their entire patient population; and pharmacy coordination infrastructure for the post-prescription patient journey. Generic video-first platforms handle the visit. A GLP-1 telehealth program needs everything around the visit to run just as smoothly.
A Note From the Field
The GLP-1 brands that navigated 2025's regulatory shift without major disruption had one thing in common: they had already built the clinical infrastructure required for compliance. Rigorous intake, documented provider reviews, follow-up workflows baked into the platform. For them, the regulatory shift wasn't a crisis; it was a market correction that removed less disciplined competitors. The brands entering the GLP-1 space now have the advantage of building into a cleaner regulatory environment, as long as they choose infrastructure that can support the clinical model the moment demands.
Conclusion
GLP-1 telehealth is not a simpler business than it was three years ago, but it's a cleaner one. The rules are clearer, patient demand remains strong, and the competitive advantage belongs to brands that can execute a compliant, clinically rigorous program at scale. That requires a platform built for the full patient journey: intake that screens effectively, prescribing that connects to the clinical record, follow-up that occurs systematically, and fulfillment that closes the loop between prescription and medication delivery.
Bask Health is built for exactly this model, giving GLP-1 telehealth brands the infrastructure to run a compliant, scalable program without stitching together a patchwork of disconnected tools.
References
- U.S. Food and Drug Administration. (2025). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- Health Resources and Services Administration (HRSA). (n.d.). What is telehealth? https://www.hrsa.gov/telehealth/what-is-telehealth
- U.S. Department of Health & Human Services, Office for the Advancement of Telehealth. (n.d.). Getting started with telehealth. https://telehealth.hhs.gov/providers/getting-started
